ArticleCureus2025
Dupilumab-Induced Graves' Disease in an Adult With Chronic Rhinosinusitis and Nasal Polyposis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of dermatology targeted immunotherapies on autoimmune thyroid diseases: cytokine-network crosstalk and thyroid safety.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and IL-13, is widely used for the treatment of type 2 inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Although generally well-tolerated, dupilumab has been linked to rare thyroid-related events. We report a case of Graves' disease (GD) in a 47-year-old man with severe nasal polyposis who developed heat intolerance and weight loss within six to eight weeks of starting dupilumab. Laboratory tests confirmed thyrotoxicosis with positive thyroid-stimulating hormone receptor antibodies (TSHR-Ab), leading to a GD diagnosis. The patient was started on methimazole and remains stable on both methimazole and dupilumab. The temporal association between dupilumab initiation and the detection of TSHR-Ab suggests a possible link between dupilumab therapy and the development of GD. This may be mediated by a shift from Type 2 helper T cells (Th2) to Type 1 helper T cells (Th1) immune dominance, which is known to promote autoimmune thyroid activity. Such a mechanism is biologically plausible and consistent with current immunopathogenic models of GD. This case adds to the limited literature on dupilumab-associated autoimmune thyroid disease. Physicians should consider monitoring thyroid function in patients on dupilumab, especially those with immune-mediated conditions. Further studies are needed to clarify this mechanism and guide screening guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.